Cytokines and the pathogenesis of non-alcoholic steatohepatitis

Gut

Volumn 54, Issue 2, 2005, Pages 303-306

  Diehl, A M ^a,b   Li, Z P ^c   Lin, H Z ^c   Yang, S Q ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; CYTOKINE; FIBRINOGEN; HORMONE; INSULIN; INTERLEUKIN 10; LEPTIN; NEUROTRANSMITTER; NORADRENALIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL MODEL; FATTY LIVER; INFLAMMATION; INSULIN RESISTANCE; LEPTIN DEFICIENCY; LIPID STORAGE; LIVER CELL; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; LIVER NECROSIS; METABOLIC DISORDER; METABOLIC SYNDROME X; NATURAL KILLER CELL; NONALCOHOLIC FATTY LIVER; OBESITY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; STELLATE CELL; TH2 CELL; VISCERAL FAT DEPOT;

ANIMALS; CYTOKINES; FATTY LIVER; HUMANS; LIVER CIRRHOSIS; METABOLIC SYNDROME X;

EID: 12344332455     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2003.024935     Document Type: Review

References (67)

1. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASlD Single Topic Conference. Hepatology 2003;37:1202-19.
2. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23.
3. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001;21:27-41.
4. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000;343:1467-76.
5. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960-7.
6. Rajala MW, Scherer PE. Minireview: The adipocyte-at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003;144:3765-73.
7. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003;144:2195-200.
8. Chaldakov GN, Stankulov IS, Hristova M, et al. Adipabiology of disease: adipokines and adipokine-targeted pharmacology. Curr Pharm Des 2003;9:1023-31.
9. Katsuki A, Sumida Y, Urakawa H, et al. Increased visceral fat and serum levels of triglyceride are associated with insulin resistance in Japanese metabolically obese, normal weight subjects with normal glucose tolerance. Diabetes Care 2003;26:2341-4.
10. Lebovitz HE. The relationship of obesity to the metabolic syndrome. Int J Clin Pract Suppl 2003;134:18-27.
11. Kelley DE, McKolanis TM, Hegazi RA, et al. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 2003;285:E906-16.
12. Chalasani N, Deeg MA, Persohn S, et al. Metabolic and anthropometric evaluation of insulin resistance in nondiabetic patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003;98:1849-55.
13. Kim JK, Fillmore JJ, Chen Y, et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A 2001;98:7522-7.
14. Tobe K, Suzuki R, Aoyama M, et al. Increased expression of the sterol regulatory element-binding protein-1 gene in insulin receptor substrate-2(-/-) mouse liver. J Biol Chem 2001;276:38337-40.
15. Misra A, Garg A. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Medicine 2003;82:129-46.
16. Kim JK, Kim YJ, Fillmore JJ, et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001;108:437-46.
17. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature 2002;420:333-6.
18. Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev 2003;14:447-55.
19. Fernandez-Real JM, Lopez-Bermejo A, Casamitjana R, et al. Novel interactions of adipanectin with the endocrine system and inflammatory parameters. J Clin Endocrinol Metab 2003;88:2714-18.
20. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000;102:1296-301.
21. Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000;96:1723-32.
22. Kern PA, Di Gregorio GB, Lu T, et al. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 2003;52:1779-65.
23. Bruun JM, Lihn AS, Verdich C, et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003;285:E527-33.
24. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 2003;14:137-45.
25. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-95.
26. Pajvani UB, Du X, Combs TP, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications far metabolic regulation and bioactivity. J Biol Chem 2003;278:9073-85.
27. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003;423:762-9.
28. Stefan N, Stumvoll M. Adiponectin-its role in metabolism and beyond. Horm Metab Res 2002;34:469-74.
29. Wang Y, Xu A, Knight C, et al. Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity. J Biol Chem 2002;277:19521-9.
30. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-6.
31. Harada K, Shen WJ, Patel S, et al. Resistance to high fat diet-induced obesity and altered expression of adipose-specific genes in HSL-deficient mice. Am J Physiol Endocrinol Metab 2003;285:E1182-95.
32. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003;148:293-300.
33. Gabriely I, Barzilai N. Surgical removal of visceral adipose tissue: effects on insulin action. Curr Diab Rep 2003;3:201-6.
34. Tsukamoto H, Lu SC. Current concepts in the pathogenesis of alcoholic liver injury. FASEB J 2001;15:1335-49.
35. Sasaki Y, Wands JR. Ethanol impairs insulin receptor substrate-1 mediated signal transduction during rat liver regeneration. Biochem Biophys Res Commun 1994;199:403-9.
36. Mohr L, Tanaka S, Wands JR. Ethanol inhibits hepatocyte proliferation in insulin receptor substrate 1 transgenic mice. Gastroenterology 1998;115:1158-65.
37. Solomon SS, Mishra SK, Cwik C, et al. Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor-alpha in liver cells. Horm Metab Res 1997;29:379-82.
38. Yu JG, Javorschi S, Hevener AL, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002;51:2968-74.
39. Enomoto N, Takei Y, Hirose M, et al. Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferator-activated receptor-(gamma), Pioglitazone. J Pharmacol Exp Ther 2003;306:846-54.
40. Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003;37:343-50.
41. Xu A, Wang Y, Keshaw H, et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003;112:91-100.
42. Green RM. Hepatic metabolism and not simply the metabolic syndrome. Hepatology 2003;38:14-17.
43. Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003;289:1799-804.
44. Bugianesi E, Leone N, Vann E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-40.
45. Hui JM, Kench JG, Chitturi S, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003;38:420-7.
46. Matteoni C, Younossi ZM, McCullough A. Nonalcoholic fatty liver disease: A spectrum of clinical pathological severity. Gastroenterology 1999;116:1413-19.
47. Martinez-Chantar ML, Corrales FJ, Martinez-Cruz LA, et al. Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A. FASEB J 2002;16:1292-4.
48. Ip E, Farrell GC, Robertson G, et al. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 2003;38:123-32.
49. Koteish A, Diehl AM. Animal models of steatosis. Semin Liver Dis 2001;21:89-104.
50. Roskams T, Yang SQ, Koteish A, et al. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol 2003;163:1301-11.
51. Honda H, Ikejima K, Hirose M, et al. Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver. Hepatology 2002;36:12-21.
52. Saxena NK, Ikeda K, Rockey DC, et al. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 2002;35:762-71.
53. Ikejima K, Takei Y, Honda H, et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 2002;122:1399-410.
54. Potter JJ, Mezey E. Leptin deficiency reduces but does not eliminate the development of heptic fibrosts in mice infected with Schistosoma mansoni. Liver 2002;22:173-7.
55. Leclercq IA, Forrell GC, Schriemer R, et al. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 2002;37:206-13.
56. Tang M, Potter JJ, Mezey E. Leptin enhances the effect of transforming growth factor beta in increasing type I collagen formation. Biochem Biophys Res Commun 2002;297:906-11.
57. Saxena NK, Saliba G, Floyd JJ, et al. Leptin induces increased alpha2(I) collagen gene expression in cultured rat hepatic stellate cells. J Cell Biochem 2003;89:311-20.
58. Marra F. Leptin and liver fibrosis: a matter of fat. Gastroenterology 2002;122:1529-32.
59. Anania FA. Leptin, liver, and obese mice-fibrosis in the fat lane. Hepatology 2002;36:246-8.
60. Hoffmann KF, Cheever AW, Wynn TA. IL-10 and the dangers of immune polarization: excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis. J Immunol 2000;164:6406-14.
61. Li Z, Lin HZ, Yang SQ, et al. Murine leptin deficiency alters Kupffer cell production of cytokines that regulate the innate immune system. Gastroenterology 2002;123:1304-10.
62. Godfrey DI, Hammond JL, Poulton LD, et al. NKT cells: facts, functions and fallacies. Immunol Today 2000;21:573.
63. Guebre-Xabier M, Yang SQ, Lin HZ, et al. Altered hepatic lymphocyte subpopulations in obesity-related fatty livers, Hepatology 1999;31:633-40.
64. Commins SP, Marsh DJ, Thomas SA, et al. Norepinephrine is required for leptin effects on gene expression in brown and white adipose tissue. Endocrinology 1999;140:4772-8.
65. Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002;111:305-17.
66. Crispe IN. Do natural T cells promote liver regeneration? Hepatology 2000;31:1022-4.
67. Oben JA, Roskams T, Yang S, et al. Norepinephrine induces hepatic fibrogenesis in leptin deficient ob/ob mice. Biochem Biophys Res Commun 2003;308:284-92.